Hi, Kathy,

Have you considered raloxifene?  The study is ongoing, but the results
with raloxifene appear better than tamoxifen, without the side effects,
for risk of invasive recurring estrogen-responsive tumors.  There was
no increase in endometrial tumors, and it offers protection against
osteoporosis and cardiovascular disease.  The URL for the story on
Medscape is:
http://www.medscape.com/medscape/cno/1999/ASCO/Story.cfm?story_id=663

I'm only sending this to the list because you requested we not email
you directly.

May it be G-d's will that you have a complete cure and a rapid, full
recovery.

Jonathan

      Never does nature say one thing and wisdom another.
                                                  -  Juvenal
         Only G-d knows the formula for mother's milk

             ***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html